In GBM xenografted tumors, ASO + Erlotinib treatment resulted in significantly lower proliferation indices (by Ki-67 staining) and higher apoptosis level (by cleaved caspase 3) comparing with monotherapy (Extended data Fig. 8f, g). Here, MKI67 is linked to glioblastoma.